Intramuscular Neuroleptics in Schizophrenia: Clinical Efficacy and Side-Effect

2015 ◽  
pp. 131-146
Author(s):  
D. J. MacCrimmon ◽  
B. Saxena
Keyword(s):  
Clinical Efficacy ◽  
Side Effect

scholarly journals CLINICAL EFFICACY OF RAJAH PRAVARTINI VATI IN THE MANAGEMENT OF ARTAVA KSHAYA (OLIGOMENORRHOEA)

2020 ◽  
Vol p4 (06) ◽  
pp. 2480-2485
Author(s):  
Chauhan Monika ◽  
Makeem Rita
Keyword(s):  
Clinical Trial ◽  
Blood Flow ◽  
Heart Disease ◽  
Clinical Study ◽  
Clinical Efficacy ◽  
Clinical Assessment ◽  
Side Effect ◽  
Endocrine Disorders

A clinical trial was carried out on 30 oligomenorrhoea [ArtavaKshaya] patients aged between 18 to 35 years having complaints of irregular, scanty and painful menstruations. The patients were registered from OPD and IPD of Patanjali Ayurveda College, Haridwar. They were administrated Rajahpravartini Vati for three months in a dose of 250mg twice daily. The specific investigations were done in order to exclude TB endometritis, endocrine disorders, diabetes and heart disease. The clinical assessment was carried out in thirty days intervals. It is inferred that the study discloses the effect of Rajahpravartini Vati on irregularity of interval of menstruation [90.47%], duration of menstruation [79.37%], amount of blood flow [90.00%] and pain during menstruation [100.00%] which were highly significant in clinical study. No untoward side effect was noticed during clinical trial.

A Multicentre, Randomized Study of FLAG Treatment in China(CHORT).

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 948-948 ◽  
Author(s):  
Hua Yan ◽  
Zhi-Xiang Shen ◽  
Jianxiang Wang
Keyword(s):  
Clinical Efficacy ◽  
Side Effect ◽  
De Novo ◽  
Induction Treatment ◽  
Refractory Disease ◽  
Efficacy And Safety ◽  
Female Ratio ◽  
Group A ◽  
First Relapse ◽  
Refractory Aml

Abstract Introduction: Adult de novo patients with acute myeloid leukemia (AML) may achieve 70%-80% of clinical remission after induction treatment, but unfortunately some proportion of them will get relapse, and the prognosis in these patients is quite poor. Clinicians have been devoted themselves to exploring new effective strategies to re-induce remission in these kind of population including FLAG, which containing fludarabine, cytosine arabinoside (Ara-C), plus granulocyte colony-stimulating factor (G-CSF). FLAG was proved to be one of the most effective salvage treatments in relapsed or refractory AML patients. Our study was designed to assess the efficacy and safety of FLAG in Chinese AML patients and further to compare the clinical efficacy and safety between different dosage of Ara-C in FLAG treatment. Methods: This is multicentre, open-label, randomized clinical trial. Relapsed or refractory non-M3 AML patients were randomly assigned to 2 treatment group. Group A: 30mg/m2/d of fludarabine intravenous infusion through d1-d5, plus G-CSF 300μg/d, starting 24 hours before treatment and continuing to d5, 1.0g/m2 of Ara-C intravenously infusion from day 1 through 5, abbreviated as FLAG 1.0. Group B: fludarabine and G-CSF were used as same as those in Group A, but dosage of Ara-C increased to 2.0g/m2 daily from d1-d5, named as FLAG 2.0. Results: Between 2006 and 2008, 398 cases of patients from 72 medical centers in China were enrolled into the study with informed consent. 177 cases were entered into analysis, with median age of 39 yrs (range 16–80) and male: female ratio of 1.7:1. 97 cases were assigned into FLAG 1.0 whereas 80 in FLAG 2.0. 73 (41.7%) of patients were diagnosed as M2, 33(18.9%) in M4, 33 (18.9%) in M5, and the other 38 in other subtype of leukemia. And 52/177 cases (29.4%) were in first relapse, while 51 (28.8%) in multi-relapse and 74 (41.8%) in refractory disease. Totally 120 out of 177 patients achieved response remission (67.8%) including 88 (49.7%) in complete remission (CR) and 32 (18.1%) in partial remission (PR). 18 cases (10.2%) had stable disease, 20 (11.3%) had progressive disease, 10 (5.6%) in non-response, and 9 cases died. Among these 9 cases, 8 suffered from serious infection and fatal bleeding during bone marrow suppression and another 1 died due to psychological obstacles. The main side effect during treatment were neutropenia (77.4%, with neutrophil ≤ 0.5×109/L ) , thrombocytopenia (73.4%, with platelet count ≤ 50×109/L), nausea and vomiting (41.8%), and infection (54.8%), but most of them were moderate and the patients got recovery by using supportive treatment. Patients in first relapse had better RR (81.2%) when compared to those in multi-relapse or in refractory disease (55.8% and 64.8%, p=0.004). And, M2 patients had higher RR (76.8%) than those in M4 (58.9%) and similar to the response in M5 patients (76.5%). More of interest, among 80 patients who received FLAG 2.0 treatment, 42 (52.5%) achieved CR, while 45 out of 97 (46%) got CR in FLAG 1.0. And most important, the side effect including the hematological or non-hematological toxicities were comparable between two groups except the neutropenia (82.8%: 71%, p=0.019) and oral ulcer (27.5%:15%, p<0.001). Conclusion: FLAG was proven to have good clinical efficacy in refractory or relapsed Chinese AML patients with well tolerated toxicities. Enhanced Ara-C dosage (FLAG 2.0) had better clinical response although it didn’t reach to the statistical difference, with comparable and manageable side effects, when compared to those in FLAG1.0 treatment. Long-term follow-up were warranted to properly evaluate the efficacy of FLAG treatment, and to compare the therapeutic benefit between FLAG 1.0 and FLAG 2.0 treatment in these relapsed or refractory AML patients.

scholarly journals Clinical efficacy of Unani formulations in psoriasis (Da-us-Sadaf): a case report

2020 ◽  
Vol 6 (6) ◽  
pp. 804
Author(s):  
Syed Shamsul Hasan Tariq
Keyword(s):  
Case Report ◽  
Side Effects ◽  
Physical Examination ◽  
Clinical Efficacy ◽  
Side Effect ◽  
Male Child ◽  
Burning Pain ◽  
Scalp Psoriasis ◽  
Multiple Patches ◽  
Scaly Skin

<p>A seven-year-old male child suffering from multiple patches over the scalp with severe burning, pain, and scaly skin, came for treatment in government Unani dispensary, Majajpur, Bharatpur, Rajasthan, India. The patient has lesions and erythema with some papules over the nape of the neck. After the proper history, physical examination, positive auspitz sign, candle grease sign and grattage test he was diagnosed as a patient of scalp psoriasis. The patient was treated with Unani drugs; sharbat murakkab musaffi khoon, arq shahatra and marham safed kafoori to evaluate the efficacy of drugs and to avoid any side effects and recurrence of the disease. The patient showed excellent and admirable results within 90 days of treatment and marked remission was found in all features without any side effect, recurrence and complications.</p>

scholarly journals Clinical efficacy and safety of lurasidone in schizophrenia: 8 week randomized double blind active controlled trial

2020 ◽  
Vol 7 (5) ◽  
pp. 817
Author(s):  
Unnati Saxena ◽  
Anuradha Nischal ◽  
Anil Nischal ◽  
Abbas Ali Mahdi ◽  
Manu Agarwal ◽  
...  
Keyword(s):  
Clinical Efficacy ◽  
Side Effect ◽  
Rating Scale ◽  
Controlled Trial ◽  
Treatment Modalities ◽  
First Episode ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Syndrome Scale ◽  
Negative Syndrome

Background: Schizophrenia comprises a group of disorders with heterogeneous etiologies, it includes patients whose clinical presentations, treatment response, and courses of illness vary. This study was carried to study the clinical efficacy and safety of Lurasidone versus Risperidone on psychopathology and cognition in patients with first episode of schizophrenia.Methods: Patients diagnosed with first episode of schizophrenia were enrolled in the study. Patients were randomized to 80 mg/d (n = 27) of Lurasidone or 6mg/d (n = 27) of Risperidone. Efficacy assessments included Positive and Negative Syndrome Scale (PANSS) scores, Schizophrenia cognition rating scale (SCoRS). IL-6 estimation was done and safety assessment was done using UKU side effect rating scale.Results: During the eight weeks of study; significant improvement was observed in PANSS total and all its subscale scores with both Lurasidone and Risperidone. Mean change in PANSS scores were not significant between the groups (-32.93 vs -35.33 p>0.05). Mean change in SCoRS scores were significantly higher in Lurasidone group as compared to risperidone group (-8.43 vs -2.34, p<0.001). Significant reduction in the IL-6 levels with both the groups but mean change in IL-6 levels were not significant between the group (-10.47 vs -8.31, p>0.05). UKU side effect rating scores were significantly higher with Risperidone as compared to Lurasidone (p<0.001).Conclusions: Lurasidone is as effective as Risperidone in improving psychopathology in patient of schizophrenia. Lurasidone proved more efficacious in improving cognition as compared to Risperidone. Both the treatment modalities are efficacious in lowering IL-6 levels. Lurasidone causes less adverse effects as compared to Risperidone.

scholarly journals Integrated Chinese and Western Medicine for the Treatment of Acne Associated Blepharokeratoconjunctivitis Case 1

2019 ◽  
Vol 3 (1) ◽  
Author(s):  
Mingmei Gao ◽  
Chengyun Liu
Keyword(s):  
Chinese Medicine ◽  
Oral Administration ◽  
Young Woman ◽  
Clinical Efficacy ◽  
Western Medicine ◽  
Side Effect ◽  
Causes Of Disease ◽  
Localized Treatment

Abstract: This article reported a case of acne associated blepharokeratoconjunctivitis (BKC) in a young woman. During her pregnancy, to reduce the systemic use of drugs due to its side effect, localized eye drop, oral administration of Chinese medicine and fumigation treatment were adopted. In integrated Chinese and Western medicine treatments, localized treatment simultaneously with the intrinsic conditioning of the patient’s physique could treat both the symptoms and root causes of disease. It can effectively improve clinical efficacy, shorten the course of the disease and reduce patient suffering and recurrence. 

Mechanism of Action of Aripiprazole Predicts Clinical Efficacy and a Favourable Side-Effect Profile

2004 ◽  
Vol 18 (3) ◽  
pp. 375-383 ◽  
Author(s):  
Tsuyoshi Hirose ◽  
Yasufumi Uwahodo ◽  
Sakiko Yamada ◽  
Takashi Miwa ◽  
Tetsuro Kikuchi ◽  
...  
Keyword(s):  
Clinical Efficacy ◽  
Mechanism Of Action ◽  
Side Effect ◽  
Side Effect Profile ◽  
Favourable Side Effect Profile

Conjunctival oedema: a side-effect of cyclosporin toxicity and a consequence of obesity

1996 ◽  
Vol 135 (1) ◽  
pp. 146-147 ◽  
Author(s):  
E. Papadavid ◽  
J. Yell ◽  
T.J. Ryan
Keyword(s):  
Side Effect

Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial

1997 ◽  
Vol 27 (8) ◽  
pp. 860-867 ◽  
Author(s):  
V.A. VARNEY ◽  
J. EDWARDS ◽  
K. TABBAH ◽  
H. BREWSTER ◽  
G. MAVROLEON ◽  
...  
Keyword(s):  
Clinical Efficacy ◽  
Specific Immunotherapy ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document